| Sandoz Pharmaceuticals AG - Rivastigmin Patch Sandoz 15, Transdermales Pflaster |
| 63164 | | 03 | | Rivastigmin Patch Sandoz 15 | | Transdermales Pflaster | | N06DA03 | | Rivastigmin | | 13.03.2014 | | |
|
| Composition |
| rivastigminum 27 mg, butylis methacrylatis et methylis methacrylatis polymerisatum, acrylic adhesive, int-rac-alpha-tocopherolum, silicone adhesive, dimeticonum, Trägermaterial: poly(ethylenis terephthalas), Drucktinte (Beige): ad praeparationem pro 15 cm², cum liberatione 13.3 mg/24h. |
| Packungsbestandteile |
| Timbre transdermique | | | | | Principe actif | Concentr. |
|---|
| Rivastigmine | 27 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Rivastigmine | 27 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| | | | | | | | | | 13.3mg / 24h | | | Dimeticone | | | | | 15 cm | | | | | | | | | | | | | Trägermaterial | | | | |
| |
|
|
